DavidGrahamJones
Well-Known Member
- Messages
- 3,263
- Type of diabetes
- Type 2
- Treatment type
- Other
- Dislikes
- Newspapers
The quality of the images obtained from Optomap is not good enough for diabetic eye screening.
Interesting. The company which is now owned by Nikon seem to imply something different.
"Our core devices produce ultra-widefield (UWF™), high resolution optomap images of approximately 82% or 200◦ of the retina, something no other device is capable of doing in a single capture. An optomap image provides a bigger picture and more clinical information which facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration."
Also the BMJ reported on "A randomised trial of non-mydriatic ultra-wide field retinal imaging versus usual care to screen for diabetic eye disease: rationale and protocol for the Clearsight trial". Their conclusion was "NM UWF imaging is a highly promising screening option for diabetic eye disease. The Clearsight trial will determine whether NM UWF imaging improves detection of clinically important eye disease compared with current practice and, if so, should help address an important gap in diabetes care."
We might see them . . . . . one day.